Bluebird Bio Inc. (NASDAQ:BLUE) shares rose 1.8% during trading on Wednesday . The company traded as high as $57.00 and last traded at $55.89, with a volume of 706,223 shares trading hands. The stock had previously closed at $54.91.

BLUE has been the topic of a number of research analyst reports. Vetr lowered Bluebird Bio from a “strong-buy” rating to a “sell” rating and set a $44.44 price target on the stock. in a report on Wednesday, June 8th. Jefferies Group reissued a “buy” rating and set a $80.00 price target on shares of Bluebird Bio in a report on Friday, July 8th. Leerink Swann reissued a “buy” rating on shares of Bluebird Bio in a report on Monday, June 13th. Zacks Investment Research lowered Bluebird Bio from a “hold” rating to a “sell” rating in a report on Monday, May 9th. Finally, Cantor Fitzgerald initiated coverage on Bluebird Bio in a report on Thursday, June 2nd. They set a “hold” rating and a $42.00 price target on the stock. Six analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Bluebird Bio has an average rating of “Buy” and a consensus price target of $82.50.

The firm’s market capitalization is $1.86 billion. The company has a 50 day moving average price of $52.56 and a 200 day moving average price of $46.99.

Bluebird Bio (NASDAQ:BLUE) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported ($1.59) earnings per share for the quarter, missing the consensus estimate of ($1.44) by $0.15. The firm earned $1.55 million during the quarter, compared to the consensus estimate of $2.01 million. During the same period in the prior year, the company earned ($1.57) earnings per share. Bluebird Bio’s revenue for the quarter was down 68.6% compared to the same quarter last year. Equities research analysts predict that Bluebird Bio Inc. will post ($6.14) earnings per share for the current fiscal year.

In other news, insider David Davidson sold 1,000 shares of the company’s stock in a transaction dated Wednesday, June 15th. The stock was sold at an average price of $40.11, for a total transaction of $40,110.00. Following the completion of the transaction, the insider now directly owns 10,600 shares of the company’s stock, valued at $425,166. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric Sullivan sold 2,807 shares of the company’s stock in a transaction dated Wednesday, July 20th. The stock was sold at an average price of $45.04, for a total value of $126,427.28. Following the transaction, the insider now directly owns 4,656 shares of the company’s stock, valued at $209,706.24. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Bluebird Bio stock. Dimensional Fund Advisors LP increased its stake in shares of Bluebird Bio Inc. (NASDAQ:BLUE) by 6.3% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 74,831 shares of the company’s stock after buying an additional 4,454 shares during the period. Dimensional Fund Advisors LP owned approximately 0.20% of Bluebird Bio worth $4,806,000 at the end of the most recent reporting period.

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.